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9ABSTRACT
Background: Functional dyspepsia (FD) has been defined as persistent or recurrent abdominal
pain or discomfort centred in the upper abdomen without any evidence of organic or
biochemical abnormality. The etiology of FD remains unknown, with inconclusive evidence for
several pathophysiologic factors including Helicobacter pylori (Hp) infection, gastric motility
disorders, altered gastric sensitivity or disturbances in acid secretion. Although Hp is associated
with peptic ulcer disease, treatment studies of Hp eradication in functional dyspepsia have
shown inconclusive results. This study evaluates the effect of Hp eradication on symptoms and
quality of life in FD, the role of gastric emptying (motility) in Hp positive FD, and the impact of
specific properties of Hp gastritis in FD.
Patients and methods: 151 Hp positive patients with functional dyspepsia were enrolled from
the basic population of outpatients sent for gastroscopy by primary care physicians. 2150
patients were screened. In addition, 11 healthy volunteers and 11 FD patients without Hp
infection were included in the scintigraphic examination as controls. Biopsy samples from
antrum, corpus and duodenum were taken from the patients and the gastritis was scored
according to the Sydney System. Different topographical elements of the gastritis were
evaluated from 143 patients and the urease activity of the stomach was determined from 36
patients by DOB-value of 13C-urea breath test. Hp infection was also confirmed by rapid urease
test and culture. Gastric emptying was measured by a dynamic dual-tracer scintigraphic
examination in 72 patients and again in 29 after one year. Solid meal was labelled with In-111
and liquid meal with Tc-99m and simultaneous anterior and posterior projections were imaged.
The symptoms and the quality of life were evaluated by separate questionnaires. Dyspeptic
symptoms were evaluated by a unique numeric scale questionnaire after every 3 months during
the one-year follow-up and the quality of life was measured by a validated RAND 36-item
health survey 1.0 questionnaire at the baseline and after 12 months. Of the 151 patients 77
received eradication therapy for the first 2 weeks with amoxycillin 500mg q.i.d, metronidazole
400mg t.i.d, and omeprazole 20mg b.i.d; 74 patients received omeprazole 20mg b.i.d and
placebo antibiotics. In addition, every patient received an open 3-month initial medication by
omeprazole 20mg daily to standardize the acid-suppression.
Main results: In gastric emptying parameters, a tendency for slower gastric emptying and more
distal gastric content distribution was seen among patients with functional dyspepsia. After
10
multivariate analysis, the use of NSAIDs was the only statistically significant factor associated
with prolonged solid lag-time (p<0.05). Habitual smoking caused alterations in intragastric
distribution and emptying of solids. Delayed liquid emptying (T1/2) was associated with
increasing age (p<0.025). After placebo-controlled eradication therapy and 12-month follow-up,
no differences were revealed  in gastric emptying parameters between patients who had received
a successful Hp eradication therapy and patients with ongoing infection. This long-term
prospective study showed, however, the reproducibility of a scintigraphic gastric emptying
study. In the patient population, the association between the first examination and the one after
12 months was significant for both solid gastric emptying (T50, p=0.20, R=0.43) and liquid
emptying (T1/2, p=0.018, R=0.43). After one year, the dyspepsia score was 7.4±3.0 in the
treatment group with a mean symptom reduction of 28.8 % compared to baseline. In the control
group the dyspepsia score was 7.6±3.1 with the mean symptom reduction of 21.7 % (p=ns). In
addition, quality of life showed no difference between treatment group and controls after this
follow-up. In a multivariate model, female gender was the only factor independently related to
dyspeptic symptoms (p=0.02). However, heartburn (p<0.01) and regurgitation (p<0.001) were
improved during the 3-month omeprazole treatment despite the Hp status. The urease activity of
the stomach was associated with the subtype of chronic gastritis. The mean DOB-value in
patients with antrum-predominant gastritis or pangastritis was 46.8 ± 20.5, whereas patients with
corpus-predominant gastritis had a mean DOB-value of 28.6 ± 20.0 (p<0.05). There was no
statistical difference in dyspepsia scores between different types of gastritis prior to the
medication. As well, the severity of gastritis was not associated with the dyspeptic symptoms.
However, in patients with antrum-predominant gastritis, the reduction of dyspepsia was
significantly more profound among successfully Hp eradicated patients than among those with
ongoing infection.
Conclusions: Hp-positive patients with functional dyspepsia did not get benefit for their
symptoms by eradicating Hp. However, reflux-like symptoms were improved with omeprazole
treatment in these patients. Dual-tracer scintigraphic examination of gastric emptying revealed
no major alterations in gastric motility among Hp infected patients, and Hp eradication had no
effect on gastric emptying parameters during 12 months. Reproducibility of this scintigraphic
examination was good. In patients with FD, Hp positive antrum-predominant gastritis was
associated with positive treatment effect by eradicating Hp, and increased urease activity of the
stomach was associated with favourable treatment effect.
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1. INTRODUCTION
Functional dyspepsia (FD) and Helicobacter pylori (Hp) infection are among the most common
clinical issues in gastroenterology but the association of these two entities is still unclear.
Functional dyspepsia has been determined as chronic or recurrent upper abdominal pain or
discomfort for a period of at least one month, with symptoms present more than 25 percent of
the time, and an absence of clinical, biochemical, endoscopic, and ultrasonographic evidence of
any organic disease that would account for the symptoms (Talley et al. 1991 and (a)1999). Hp
infection is one of the most common bacterial infections of humans in the world. Among
Finnish subjects, the prevalence of Hp varies between 6-10% in children and 50-70% in subjects
born from 1915 to 1935 (Sipponen 1997, Ashorn et al. 1995, Rehnberg-Laiho et al. 1998). Hp
infection is strongly associated with chronic gastritis, peptic ulcer disease, gastric MALT-
lymphoma, and gastric cancer (Sipponen and Marshall 2000, Stolte and Edit 1993). However,
whether this infection can cause upper abdominal symptoms in the absence of peptic ulceration
remains unclear, and treatment studies with Hp eradication therapy in FD have reached unclear
conclusions ((b)Moayyedi et al. 2000, Danesh et al. 2000, Laine et al. 2000, Jaakkimainen et al.
1999). Chronic active Hp gastritis affecting the distal part of the stomach (antrum) is associated
with duodenal ulcer disease, whereas corpus-predominant gastritis mainly leads to loss of acid
secretory capacity and atrophy ( Sipponen and Hyvärinen 1993, Sipponen et al. 1989 and 1990,
McColl et al. 2000). The association between different types of Hp gastritis and treatment
response of FD has not been studied. 
Gastric motility includes the motor functions of the stomach which are the result of a complex
interaction of muscular and neural activity. Motor functions of the stomach and the gastric
emptying are connected together (Camilleri et al.1986, Datz 1991, Horowitz et al. 1994). Most
of the studies about functional dyspepsia and gastric motility, show a tendency to prolonged
gastric emptying in these patients (Klauser et al. 1993, Malagelada 1991), although the
relationship is not exactly clear. In addition, the role of Hp infection in gastric motility disorders
is unclear and there are only few studies about Hp eradication therapy and alterations in gastric
motility (Miyaji et al. 1999, Goh et al. 1997, Parente et al. 1998). Scintigraphic techniques are
currently considered the method of choice for the accurate and non-invasive measurement of
gastric emptying under relatively physiological conditions (Datz 1991, Horowitz et al. 1994). In
addition, because solid and liquid contents empty stomach by separate mechanisms, it is
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possible to use different markers in isotope-based examinations to obtain the optimal
information.
This study was planned to  investigate the gastric motility in Hp positive functional dyspepsia
by creating a scintigraphic system for measuring different gastric emptying parameters and to
evaluate the role of Hp eradication therapy in gastric emptying after a long-term follow-up. In
addition, the main aims were to investigate the long-term effect of Hp eradication therapy on
symptoms and quality of life in patients with FD, and to assess the impact of spesific properties
of HP gastritis in FD.
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2. REVIEW OF THE LITERATURE
2.1. Functional dyspepsia
        
2.1.1 Definition
  
The definition of dyspepsia has changed over time. The term ’dyspepsia’ derived from the
Greek words ’dys’ (bad) and ’pepsis’ (digestion), refers to symptoms thought to originate in the
upper gastrointestinal tract. Dyspepsia is divided to organic dyspepsia and functional dyspepsia
(FD) depending from the etiology of the symptoms. A widely accepted definition of functional
dyspepsia has been presented in a working-group  report by Talley et al. (1991). According to
that report, functional dyspepsia (nonulcer dyspepsia) means chronic or recurrent upper
abdominal pain or discomfort for a period of at least one month, with symptoms present more
than 25 percent of the time, and an absence of clinical, biochemical, endoscopic, and
ultrasonographic evidence of any organic disease that would account for the symptoms. 
Functional dyspepsia has been further classified to reflux-like dyspepsia (heartburn,
regurgitation), ulcer-like dyspepsia (epigastric pain), dysmotility-like dyspepsia (nausea,
vomiting, early satiety) and nonspesific dyspepsia (Talley 1991). However, the usefulness of
this subclassification based on symptoms has proved to be of minor importance ((a)Talley
1993). In clinical practice, FD is a digestive syndrome different from, although freguently
overlapping with, gastroesophageal reflux disease and irritable bowel syndrome. Some studies
have shown that analysis of the predominant (most bothersome) symptom may identify
subgroups of FD characterized by different responses to treatment (Stanghellini et al. 1996,
Meineche-Schmidt and Christensen 1998). Therefore more detailed criteria for functional
gastroduodenal disorders (Rome II criteria) based on predominant symptoms instead of
symptom clusters have been published ((a)Talley et al 1999). Symptoms of IBS occur
commonly in patients with functional dyspepsia, but if strict definitions are applied, these two
entities can usually be separated to distinct syndromes (Talley et al.1991, (a)Talley et al. 1999).
It is known that heartburn and acid regurgitation predict reflux disease extremely well (Klauser
et al. 1990). Patients with mucosal erosions in the distal esophagus are easily diagnosed having
a reflux-disease, but the objective diagnosis of reflux disease is difficult in patients with normal
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endoscopy (Dent et al. 1999). Twenty-four-hour ambulatory esophageal pH monitoring is
frequently considered to be a diagnostic golden standard (Joelsson and Johnsson 1989, Shi et al.
1995, Small et al. 1995), but it has still significant limitations and even severe reflux esophagitis
may have negative result (Dent 1998). Analysis of symptoms or a 2-week treatment-test by PPI
are probably the most useful methods for diagnosis (Dent 1998).  Therefore, patients with
predominant reflux-like symptoms are usually not classified as functional dyspepsia-patients, as
is the case in our studies. 
2.1.2 Epidemiology and natural history 
General population studies have shown dyspepsia to be a very common phenomenon. In
separate studies the prevalence of dyspepsia has been shown to be 54 % in Sweden within a 3-
month period (Agreus et al. 1994), and 50 % in Denmark within 1 year (Kay and Jorgensen
1994). Approximately 15-40 % experience dyspepsia, at least once a year, depending on the
definition of dyspepsia and on the time frame of the prevalence (Locke 1998). Although
between 0.5 % and 1% of the population annually develop new dyspepsia or reflux symptoms,
the prevalence in the population is stable as the rate of loss of symptoms and the rate of
development of symptoms in new subjects balance each other out (Agreus et al.1998). Several
studies have addressed symptom turnover and repeated the findings that dyspeptic symptoms are
persistent and recurrent. Jones and Lydeard (1992) revealed that during 2 years only 26 % of the
patients had become symptom-free. In addition, 86 % of those with frequent dyspepsia reported
the same symptoms during the next 12-20 months (Talley et al. 1992), and only 25 % of
dyspeptics have shown to be symptom-free after five years (Kay and Jorgensen 1994). However,
only 25 % of patients with dyspepsia seek medical advice (Jones et al. 1990). Sociodemographic
and environmental factors have not been shown unequivocally to be predictors of dyspepsia in
the literature, while psychosocial factors have been shown to contribute to the morbidity
(Wiklund and Butler-Wheelhouse1996). For all visits at primary health care, dyspepsia covers
2-6 % in western countries (Brown and Rees 1990, Heikkinen et al. 1996). Approximately one
half of subjects with dyspepsia have an underlying organic lesion (Kagevi et al 1989, Klauser et
al 1993). In a population-based study in Finland by Heikkinen et al. (1995), 400 consecutive
unselected patients with dyspepsia were thoroughly investigated. The final diagnosis was
functional dyspepsia for 34 % of these patients. Most common organic causes were oesophagitis
15 %, peptic ulcer 13 %, and lactose intolerance 9 %.    
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2.2. Helicobacter pylori infection
Hp is a gram-negative bacteria first described by Warren and Marshall (1983). It colonises
human stomach which is the only known natural reservoir of this microbe. The discovery of HP
has revolutionized the pathophysiological and clinical approach to diseases of the upper GI-
tract, especially peptic ulcer disease.     
2.2.1 Epidemiology
Hp infection is one of the commonest bacterial infections of humans in the world. It is generally
acquired during childhood (Broutet et al. 1999, Sipponen et al. 1995), and in practical view,
persists indefinitely if left untreated. The annual spontaneous elimination of the bacteria is only
0.5-2 % (Xia and Talley 1997). The prevalence of Hp infection is associated with low socio-
economic status and it is increased in developing countries (Broutet et al. 1999). In Finland, the
prevalence of Hp infection in children is 6-10 % (Ashorn et al. 1995, Rehnberg-Laiho et al.
1998), and the infection is acquired mainly before the age of seven. The overall prevalence is
dependent on so called cohort-phenomenon (Roosendaal et al. 1997). Among finnish subjects
born between 1915-35 the prevalence of Hp infection is 50-70 % and in subjects born between
1955-75, 15-35% of cases are Hp positive (Sipponen 1997).
2.2.2 H.pylori and pathogenesis of gastroduodenal disease
Colonisation of the gastric mucosa by Hp evokes a local inflammatory response, resulting in
further mucosal injury (Go and Crowe 2000, Blaser 1992). This inflammation is usually a
lifelong, stabile or slowly progressive disease, which may cause divergent effects on acid
secretion depending on the “stage” or type of the gastritis (Sipponen and Hyvärinen 1993,
Blaser 1992, El-Omar et al. 1993, McColl and El-Omar 1996, Anand and Graham 1999, Villako
et al. 1991). 
In patients with duodenal ulcer disease, the infection is accompanied by an increase in both
basal and stimulated acid output (El-Omar et al. 1993, 1995). Hypergastrinaemia and reduction
in gastric somatostatin levels are associated with that phenomenon (Larsson and Houggaard
1994). In addition, gastric hypersecretion contributes to the development of gastric metaplasia
in the proximal part of the duodenum and the duodenal mucosa becomes increasingly vulnerable
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to peptic acid attack and subsequent ulceration (Wyatt et al. 1990, Malfertheiner and Bode 1993,
Tytgat et al. 1993). The risk of developing gastric or duodenal ulceration during a 10-year
follow-up has been shown to be 11% in patients with Hp infection compared to less than 1% in
subjects without Hp gastritis (Sipponen et al. 1990). 
It is frequently considered that chronic active gastritis affecting the antrum is associated with
duodenal ulcer disease, whereas corpus-predominant gastritis mainly leads to loss of acid
secretory capacity and atrophy increasing the risk of gastric carcinoma (McColl et al. 2000,
Anand and Graham 1999, Sipponen and Hyvärinen 1993, Sipponen et al. 1989 and 1990,
Cederberg et al. 1991, McColl and El-Omar 1996). In some cases, Hp gastritis is progressing
towards gastric mucosal atrophy after years or decades with chronic infection (Genta 1997), and
it seems that the grade of atrophy plays a major role in carcinogenesis whether the infection is
antrum-predominant or corpus-predominant (Sipponen and Marshall 2000). If there is a severe
atrophy in antrum and corpus, the risk for gastric cancer is approximately 90 times higher than
in subjects with a healthy gastric mucosa (Sipponen and Marshall 2000). In addition of
increased risk to develop gastric carcinoma, chronic Hp infection is associated with
development of primary gastric lymphoma (MALT) (Stolte and Edit 1993).
Whether chronic Hp infection can cause dyspeptic symptoms in the absence of any organic
causes mentioned earlier remains unclear ((b)Moayyedi et al. 2000, Laine et al. 2000,
Armstrong 1996, Labenz and Rokkas 1997, (b)Talley 1993, Lambert 1993). Assessing the
symptoms of FD and Hp is a difficult task.  Some studies have been able to connect ’ulcus-like’
symptoms (mainly pain in the epigastrium) and Hp infection (Hovelius et al. 1994, Thurmer et
al. 1996, Lai et al. 1996). Burping and bloating have been associated with Hp infection, but
mainly, no clear symptom profile differences between HP positive and negative FD patients
have been found (Armstrong 1996). Hp is common in asymptomatic healthy subjects. In most
epidemiological studies (Lambert 1993), as well as in meta-analysis by Armstrong (1996), the
Hp prevalence among patients with FD is still higher than in asymptomatic subjects.
Considering the possible pathophysiologic mechanisms of FD, no difference in acid output was
found between Hp positive and Hp negative FD patients (Tucci et al. 1992). In addition, studies
about gastric motility and Hp, as discussed in chapter 2.3.3, have given controversial results.
Likewise, gastric sensitivity to mucosal irritation (George et al 1991) or distension to luminal
dilatation (Saslow et al. 1998) are not altered by Hp infection. 
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2.2.3 Diagnosis
Hp infection can be diagnosed by invasive tests in gastroscopy or by non-invasive tests. Today,
several excellent tests for clinical use are available but no single test is optimal. Hp protects
itself from the bactericidical effects of gastric acid by producing urease, which, by hydrolysing
urea to ammonia, neutralises the acid in the immediate microenvironment of the bacterium
(Marshall et al. 1990). Based to this urease reaction, several diagnostic approaches have been
developed.
Histological examination of the biopsy samples from gastric mucosa has widely been considered
as the golden-standard of diagnosis of Hp infection. Of course, the accuracy of histology for the
detection of Hp is dependent of the experience of the pathologist (Maconi et al. 1999). Usually
routine haematoxylin and eosin stain or Giemsa stain are used for histological examination. At
least two biopsies from the antrum and corpus should be taken (Niemelä et al. 2000). The
amount and site of biopsy samples is especially important in patients with partial atrophic
changes in the gastric mucosa (Satoh et al. 1998). The rapid urease test is available in different
commercial forms (Hirschl and Glupczynski 1999). Sensitivity of the rapid urease test depends
upon the number of bacteria present in the biopsy sample (Midolo and Marshall 2000).
Sensitivity of the test is in the range of 75-98 % (Midolo and Marshall 2000, Marshall et al.
1987, Borromeo et al. 1987). In addition, PCR methods to detect Hp in gastric biopsy samples
are available and various assays have been developed. However, PCR techniques are not yet
useful as routine tools for the diagnosis of Hp (Hirschl and Glupczynski 1999).
Several ELISA-based serological tests are available and the accuracy of these tests is acceptable.
The sensitivity and specificity of these tests are usually between 90-95 % (Feldman et al. 1995).
Hp can also be detected from stool samples by PCR, by spesific IgA-antibodies and by detection
of Hp antigen, but so far the antigen detection method is the only test based on stool samples
which has a role in routine diagnostic use (Watanabe et al. 1998, Hirschl and Glupczynski
1999). In a large multicentre study of 500 patients the sensitivity and specificity were reported
as 94% and 91% (Vaira et al. 1998). After treatment, however, the usefulness of this method for
confirming the absence of Hp is controversial (Ishihara et al. 2000, Caselli et al. 1999).
18
2.2.4 Clinical use of diagnostic tests
In the recommendation for Hp diagnosis and treatment by the Finnish Society of
Gastroenterology, the 13C-UBT, quantitative serology and antigen detection from stool are
listed as the most suitable non-invasive tests for Hp diagnosis. Treatment effect after eradication
therapy should be confirmed by C13-UBT at least four weeks after medication (Niemelä et al.
2000). In situations with low bacterial load in gastric mucosa (treatment with acid-suppression
or antibiotics, atrophic gastritis), tests based to the urease reaction or histological examination
may give wrong negative results and quantitative serology is needed. Rapid qualitative
serological tests using whole blood are not recommended for diagnosing Hp because of the
varying diagnostic accuracy (The European Helicobacter pylori study group 1997, Niemelä et
al. 2000).
2.2.5 Aspects of 13C-urea breath test 
Principle of the diagnostic breath tests is based on the high urease activity of Hp. A minimal
dosage of isotope-labelled urea is given to the patient, and if Hp is present, the urea is
hydrolysed to isotope-labelled CO2, which circulates to the lungs and is expired in the breath
where it can be detected. The use of 14C-UBT is limited by the radioactivity of the isotope. It
can not be used in children or woman of child-bearing age, and the use of 14C-UBT is difficult
outside hospitals. 13C-UBT is a non-radioactive test, and the breath samples are analysed by gas
chromatography or isotope ratio mass spectrometry. Sensitivity and specificity of this test are
significantly over 90 % (Logan 1998). Many different protocols using 13C-urea are available for
detection of Hp (Graham and Klein 1991). A single breath sample collected at least 30 min after
administration of the substrate, and a delta-over-baseline value (DOB; i.e., an increase in the
13CO2/12CO2 isotope ratio) of 6 ‰ seems to be a suitable method for determining Hp infective
status (Klein and Graham 1993, (a,b)Logan et al. 1991)  In its classical form, a test meal and a
waiting time of approximately 30 minutes are needed in 13C-UBT, but a new modification of
this test has been published. In this tablet-based 13C-UBT the time of the procedure has been
reduced to 10 minutes, no test meal is needed and the test can be performed also during an acid-
suppression therapy (Hamlet et al. 1999). 
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13C-UBT is known to be a sensitive method specific for Hp infection ((a,b)Logan 1991), but it
is unclear to what extent it is quantitative (Graham and Klein 2000, Atherton and Spiller 1994).
In some reports, UBT values have been associated with the results of bacterial counts contained
in biopsy specimens (Peura et al. 1996), but other studies have not confirmed these findings
((b)Logan 1991). Urease concentrations differing by as much as eightfold have been detected for
different Hp strains (Dunn et al. 1990). 13C-UBT values, however, have been shown to correlate
with the severity of gastritis ((b)Logan et al. 1991, (a)Perri et al. 1998)
2.2.6 Treatment regimens for H.pylori infection
The acidity of the human stomach and the increasing antibiotic-resistance of the bacteria make
it difficult to achieve an optimal treatment for Hp infection. A large number of studies have been
carried out to evaluate different therapies. The mechanisms behind the efficacy, or lack of
efficacy, in separate treatment regimens are not fully understood. It is widely accepted that acid-
suppression and antibiotics are both needed, and most recommended regimens consist of two
antibiotics (Laheij et al. 1999, Niemelä et al. 2000, The European Helicobacter pylori study
group 1997, Unge 1996, Montague et al. 1999, Buckley and Deltenre 1997). Usually the
antimicrobial agents used are amoxycillin, tetracycline, metronidazole or tinidazole,
clarithromycin and bismuth subcitrate or ranitidine bismuth citrate. The dosages and the
duration of the different treatment protocols show variation in different nations. However, the
treatment regimens should be simple, well tolerated and achieve an eradication rate of over 80
% (The European Helicobacter pylori study group 1997). The current Finnish primary treatment
recommendations for Hp are shown in Table 1. After two treatment failures a gastroscopy
should be performed and Hp culture for resistance analysis should be obtained (Niemelä et al.
2000). 
So far no optimal treatment is available for metronidazole and clarithromycin resistant Hp
strains, although high-dose amoxycillin-omeprazole dual-therapy (Peitz et al 1999) has shown
promising results. In addition, rifabutin-based eradication therapy has been reported to be
effective in treating “non-responders” after repeatedly failed conventional therapies (Perri et al.
2000). At the moment, the metronidazole resistance is over 30 % and the clarithromycin
resistance is approximately 5 % in Finland (Glupczynski et al. 1999, unpublished data from
Helsinki University Central Hospital).
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Table 1.  
Finnish recommendation for Hp treatment in adults (Niemelä et al. 2000)
Primary treatment (1 or 2) Treatment after one failure
1) PPIx2 + Clarithromycin 500mgx2 +
Amoxycillin 1gx2,
for one week
Ranitidine bismuth citrate 400mgx2 +
Metronidazole 400mgx3 + Tetracycline
500mgx4,
for one week
2) Ranitidine bismuth citrate 400mgx2 +
Clarithromycin 500mgx2 + Amoxycillin
1gx2,
for one week
2.3. Gastric motility
        
2.3.1 Physiology
Gastric motility or gastric emptying is a physiologic phenomenon, which is still not fully
understood. The motor functions of the stomach are the result of a complex interaction of
muscular and neural activity. It includes the spontaneous electrical and contractile activity of the
gastric cells, which starts from a “pace-maker” region located in the upper part of the greater
curvature of the stomach (Minami and McCallum 1984). In general, it is widely accepted that
the motor functions of the stomach and the gastric emptying are connected together (Camilleri
et al. 1985 and1986, Datz 1991, Horowitz et al. 1994).  When solid food or liquids are
swallowed, subsequent entry into the stomach is accompanied by relaxation of the fundus
(receptive relaxation). The role of the proximal stomach is mainly controlling the
accommodation and the intragastric tonic pressure after ingested food (Datz 1991, Horowitz et
al. 1994). Antrum or distal part of the stomach fragmentates the ingested food by coordinated
contraction of the stomach walls (Datz 1991, Horowitz et al. 1994). Thus, antrum is mainly
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responsible for the emptying of solid contents, and liquids empty because of the tonic pressure
of the stomach and by the influence of gravity. Liquid emptying rate can even be normal in
gastroparesis (Datz 1991). However, solids, especially nondigestible, can also empty the
stomach via powerful phase III interdigestive migrating motor complex (MMC) contractions
that occur between meals (Datz 1991, Horowitz et al. 1994). 
Many physiological factors can alter gastric emptying. A large fatty meal with high caloric
content delays gastric emptying as well as alcohol intake (Moore et al. 1984). Also, the gastric
emptying rates differ depending on the posture of the subject (Moore et al. 1988). Acute
physical or mental stress may delay gastric emptying (Datz et al. 1990), and the emptying rate
of stomach is lower in the evening than in the morning (Goo et al. 1987). However, during
physical exercise the gastric emptying may be fast (Moore et al 1990). Sex hormones (Datz et
al. 1987) and  age (Moore et al. 1983) are also associated with alterations in gastric emptying.
Cigarette smoking seems both to alter the intragastric distribution of solids and liquids and to
delay gastric emptying ((a)Scott et al. 1993). Considering these observations listed above, it is
logical to study gastric motility disorders in functional dyspepsia. 
2.3.2 Measurement of gastric emptying
A number of approaches have been devised to evaluate gastroduodenal motility and gastric
emptying (Table 2). Scintigraphic techniques are currently considered the method of choice for
the accurate and non-invasive measurement of gastric emptying under relatively physiological
conditions (Datz 1991, Horowitz et al. 1994, Akkermans and van Isselt 1994). Solid and liquid
contents empty stomach by separate mechanisms, and for that reason different markers are
needed to obtain the optimal information. Liquid markers currently used are in a nonabsorbable
chelated form, such as Tc99m, In113m or 111InDTPA. Digestible solid markers with a high
labelling efficiency are: in vivo 99mTc-labelled chicken liver; in vitro  99mTc-labelled egg
white, potato puree, liver pate, and pancake (Akkermans and van Isselt 1994). The rate of
emptying of small indigestible solid particles mixed with a solid digestible meal, is similar to
that of digestible solids (van der Sijp et al. 1993). Scintigraphy can measure total stomach
emptying, as well as the intragastric distribution of ingesta and even smaller regions of interest
(fundus for example) in the stomach can be examined. However, scintigraphic techniques do not
have sufficient temporal resolution to quantify transpyloric flow accurately (Horowitz et al.
1994). Gastric emptying of solids is a biphasic process in which the emptying phase is preceded
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by a lag period, which probably presents the time taken for redistribution of food from the
proximal to the distal stomach and for grinding solid food into small particles for transpyloric
emptying (Horowitz et al. 1994). 
In analysing the scintigraphic data, a power exponential function is usually applied to fit the
emptying curve and to obtain gastric emptying half-times, which is the commonest method for
describing the whole emptying process (Tosetti et al. 1998). Thus, parameters which quantify
solid gastric emptying are the duration of the lag phase in minutes and the postlag emptying rate
in percentage emptied per time unit (Akkermans and van Isselt 1994). If dual-isotope method is
used with two nuclides of different energies, such as 111In and 99mTc in the same meal,  the
Compton scatter occurs. Magnitude of this error is somewhere between 20 and 30 %, and each
frame of the time-activity curve needs to be corrected (Akkermans and van Isselt 1994). Another
measurement error with underestimation of emptying rates occurs if scintigraphic detection is
made unilaterally alone (Tothill et al. 1978).
Table 2.
Techniques for measurement of gastric emptying and motility (modified from Horowitz et al.
1994)
Invasive techniques Noninvasive techniques
endoscopy scintigraphy
aspiration of gastric contents radiology
manometry ultrasound
barostat magnetic resonance imaging
applied potential tomography
electrogastrography 
radioisotopic breath testing
absorption kinetics of orally administered
drugs
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2.3.3 H.pylori and gastric motility
The role of Hp in  gastric motility disorders is still obscure. Some studies show, that Hp positive
subjects have prolonged gastric emptying compared to Hp negative subjects. These include the
observation by Mearin et al. (1995) that the postprandial antral motor activity is decreased in Hp
positive subjects compared to other dyspeptic patients. Gastric emptying alterations in Hp-
positive subjects compared to controls have been described in few studies (Tucci et al. 1992,
(b)Scott et al.1993, Fock et al. 1997, Testoni et al. 1996), whereas most publications have shown
no difference between Hp-positive and negative subjects (Caballero-Plasencia et al.1995,
Parente et al. 1998, Perri et al. 1998, Chang et al. 1996, Saslow et al. 1998, Chiloiro et al. 2001,
Rhee et al. 1999). In a scintigraphic study by Scott et al.((b)1993), a prolonged gastric emptying
and an altered intragastric distribution of food was  demonstrated in functional dyspepsia
patients, but the solid lag time was prolonged in Hp negative patients. Chang et al. (1996) found,
in 60 patients with functional dyspepsia, that delayed gastric emptying of solids was present in
about 60% of cases, and this feature was a slightly more common phenomenon among Hp
positive subjects. 
There are only few studies about the effect of Hp eradication therapy on gastric motility. In few
studies an association between Hp eradication and changes in gastric emptying have been
demonstrated (Konturek et al. 1997, Thor et al. 1996). In a studies by Goh et al. (1997) and
Parente et al. (1998), no effect on gastric emptying was found after eradication therapy. As well,
in a breath-test based study by Peitz et al.(1996) the delayed gastric emptying in dyspeptic
patients was stable after Hp eradication.
        
2.4. Etiologic aspects and treatment of functional dyspepsia
2.4.1 H.pylori eradication
The results of studies with Hp eradication therapy in FD are controversial. In uninvestigated
dyspepsia, substantial cost benefits and reduction of endoscopy workload can be achieved if all
young patients with dyspepsia in primary care are tested for Hp and positive subjects are treated
(Patel et al. 1995, Heaney et al. 1999, (a)Moayyedi et al. 2000). Therefore the “test and treat”
policy for treating dyspepsia has been widely accepted in dyspepsia management
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recommendations (The European Helicobacter pylori study Group 1997, Finnish Society of
Gastroenterology  2000). However, treatment studies of Hp positive functional dyspepsia have
given conflicting results. Different follow-up times, separate symptom questionnaires,
uneffective eradication therapies and well known placebo effect of treating functional dyspepsia
have made the results of these studies difficult to analyse. In addition, functional dyspepsia may
not be equally determined. There exist six randomised, placebo-controlled studies of Hp positive
functional dyspepsia with at least 12 month follow-up after eradication therapy and patient
number at least one hundred. In five of them ((b)Talley et al. 1999, (c)Talley et al. 1999,
Greenberg and Cello 1999, Blum et al. 1998, Froechlich et al. 2001) no differences in symptoms
between treatment group or placebo-group were detected, although in the study by (c)Talley et
al. (1999) healing of gastritis was associated with resolution of symptoms. One of these studies
(McColl et al. 1998) demonstrated a resolution of symptoms associated with eradication
therapy. In a study with smaller number of patients (n=90), Miwa et al. (2000) found no
significant improvement in symptoms of non ulcer dyspepsia in the treatment group compared
to placebo. In addition to these original publications, few abstracts considering placebo
controlled eradication therapy studies have been presented. Malfertheiner et al. (2000)
documented a statistically significant 9 % difference in dyspeptic symptoms after one year in
favour of the eradication group in a large patient material (n=860). In a recent abstract, complete
symptom relief was associated with H.pylori eradication, although there was no significant
difference in symptom scores (Bruley des Varannes et al. 2000).
In a systematic review evaluating nine studies of Hp eradication in functional dyspepsia,
(b)Moayyedi et al. (2000) concluded a benefit of eradication therapy in symptoms with risk
reduction of 9 %. In the same review, quality of life showed no improvement in meta-analysis
with three separate studies. However, two systematic analyses found no clear confirmation of
functional dyspepsia symptom relief by eradication therapy (Danesh et al. 2000, Laine et al.
2000) but a  meta-analysis by Jaakkimainen et al.(1999) observed an improvement in dyspeptic
symptoms with odds ratio of 1.9 in patients whose Hp was eradicated.
2.4.2 Motility disorders and treatment with prokinetic agents
Several clinical conditions, such as diabetes mellitus and postoperative problems, are clearly
associated with disorders in gastric motility. Many studies about functional dyspepsia and
gastric motility, shows a tendency to prolonged gastric emptying of solids in these patients
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(Quartero et al. 1998, Urbain et al. 1995, Duan et al. 1993, Rees et al. 1980, Caballero-Plasencia
et al. 1995), although the relationship is not exactly clear. In general, gastric motor dysfunction
demonstrated by scintigraphic studies, electrogastrography, or manometrical studies has been
reported in 25-60% of patients with functional dyspepsia (Malagelada 1996, Wilmer et al.
1998). However, the relationship between these findings and dyspeptic symptoms is
controversial (Caballero-Plasencia et al. 1995, Talley et al 1989, Vantrappen 1994, Wilmer et al.
1998). The association between chronic idiopathic gastric stasis and FD has been reported by
Narducci et al. (1986), patients were examined by scintigraphy and manometry. Prolonged solid
lagtime and 40 % prevalence of gastroparesis in FD patients were observed in a dynamic antral
scintigraphic study by Urbain et al. (1995). Scintigraphic study by  Scott et al. ((b)1993) showed
disturbances in intragastric distribution of contents in addition to delayed emptying of solids and
prolonged solid lagtime in FD patients. Also, in a scintigraphic study with 50 patients and 50
control subjects, delayed gastric emptying of a solid meal or of indigestible solids were reported
in 78 % and 68 % of FD patients (Caballero-Plasencia et al. 1995). However, in this study, there
was no correlation between symptoms and gastroparesis. Usually, the gastric emptying of solids
is delayed in scintigraphic studies, and the role of antral contractions in solid food emptying has
been considered to be essential (Camilleri et al. 1986, Horowitz et al. 1994). Therefore, it is
obvious that antral hypomotility, measured by ultrasonography or scintigraphy, has been
reported in FD patients (Urbain et al. 1995, Narducci et al. 1986, Stanghellini et al 1992,
Hausken et al 1993). Myoelectric function of the stomach is characterized by a cyclic electrical
pacemaker activity, so called slow waves. Gastric slow-wave disturbances can include
tachygastria, tachybradyarrhytmia or absence of the normal increase in slow wave amplitude
after ingestion of a meal (Minami and McCallum 1984, Chen and McCallum 1993). 
Prokinetic agents have been widely used for treating dyspeptic symptoms. In patients with
uninvestigated dyspepsia and a negative Hp serology, no difference in the severity of symptoms
was found in patients receiving cisapride as compared to placebo (Kearney et al. 2000).
However, cisapride provides symptomatic relief in functional dyspepsia associated with gastric
myoelectrical abnormality (Chen et al. 2000). In a systematic analysis by van Zanten et al.
(1996), cisapride has shown to be effective in 7/9 placebo-controlled studies in functional
dyspepsia, domperidone in all 7 studies reported and metoclopramide in both two studies
published. In a review article by Fisher et al. (1998), prokinetic agents were shown to be more
effective than placebo in 16/21 studies and the overall  improvement of symptoms was
suggested to be 40 to 45 percentage points greater than with placebo. In a meta-analysis by Soo
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et al. (2001), prokinetic drugs were the most effective agents in FD, but most of the published
trials were small  and studies of poor quality studies were included.
     
2.4.3 Disturbances in acid secretion and treatment with acid-suppression
Functional dyspepsia patients with Hp gastritis are shown to have an acid output comparable to
that of healthy controls (Tucci et al. 1992), but a higher acid response to gastrin-releasing
peptide (El-Omar et al. 1995). However, as mentioned earlier Hp infection has also been linked
to increased basal and stimulated acid output, the effect being most pronounced in patients with
duodenal ulceration. Because the long-term risk of getting gastric atrophy is increased in Hp
positive patients, it is likely that the role of acid secretion disturbances is dependent on the
“stage” of the current infection. 
In clinical practice,  acid-suppressive agents appear to be the most widely used medication in
FD, and even long-term treatment without specific diagnosis is very common (Meineche-
Schmidt et al. 1999, Ryder et al. 1994). It seems that treatment with antacids provides no clear
benefit and H2-blockers may offer only limited improvement of symptoms in treating functional
dyspepsia (Van Zanten et al. 1996, Nyren et al. 1986, Fisher and Parkman 1998, Soo et al.
2001). Recent studies have confirmed the positive role of proton pump inhibitors, at least in
some subgroups, of treating functional dyspepsia.  Meinache-Schmidt et al. (1999) have
reported a 3-month lasting symptom-resolution after a 4-week omeprazole treatment. In a report
by Talley et al. (1998), omeprazole appeared to be superior to placebo only in a subgroup of
patients with ’ulcer-like’ or ’reflux-like’ functional dyspepsia . In a study by Farup et al. (1999),
the patients with functional dyspepsia who responded to omeprazole treatment had a
characteristic gastro-esophageal reflux pattern. In general, the treatment response to proton
pump inhibitors is well documented but marginal. In a meta-analysis with 1225 patients, H2RA
therapy was superior to placebo and the efficacy was surprisingly even more pronounced than
that of PPI therapy (Soo et al. 2001). It should be born in mind that evaluation of treatment
responses by different pharmacological agents is difficult due to the marked, approximately 30
%, placebo-effect of treating FD (Van Zanten et al.1996, Grant Thompson 2000).  
2.4.4 Other aspects of treatment
Many authors have considered functional dyspepsia as a symptom complex with a multiple
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origin. The criteria for functional dyspepsia requires that the etiology of the symptom is not
known (Talley et al. 1991). However, hypotheses and treatment surveys have been performed.
There are only limited data from controlled studies of psychotropic medication for the treatment
of FD (Fisher and Parkman 1998), but there is evidence that psychotherapy may have positive
effects in patients with FD (Hamilton et al. 2000). In one placebo-controlled study with
mianserin, a positive effect on symptoms has been achieved (Tanum and Malt 1996).
Furthermore, psychological stress and psychiatric disease have been found to be notable risk
factors for the occurrence of upper GI symptoms (Stanghellini 1999). Also alterations in
autonomic nervous system activity (Muth et al.2000) and impaired relaxation of the proximal
stomach after meal (Tack et al. 1998) have been described in patients with functional dyspepsia.
Symptoms of irritable bowel syndrome are usually linked to dyspeptic symptoms and often
make it difficult to distinguish these two entities (Talley et al. 1991, (a)Talley et al. 1999). So far
treatment surveys of dyspepsia by fibre-products have not been published. In patients with IBS,
the presence of dyspepsia has been shown to be associated with Hp infection (Su et al. 2000).
The roles of various manners of living (tobacco, alcohol, coffee) have only minor impact on
dyspeptic symptoms (Elta et al.1990, Kay et al. 1994). Bismuth salts have shown to be
marginally more effective than placebo in FD, but there is no clear evidence that antacids,
sucralfate or misoprostol are superior to placebo (Soo et al. 2001) 
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3. AIMS OF THE STUDY
The main aims and the specific aims of the present study were:
1. To evaluate the effect of treatment on Hp positive FD
         
A. To investigate the long-term effect of Hp eradication therapy on symptoms of FD.
B. To examine whether acid-suppression therapy has impact on treatment of Hp positive FD
C. To examine, if a subgroup of patients, who clearly get benefit from Hp eradication for their
symptoms, can be found.
  
2. To investigate the role of gastric motility in Hp positive FD.
       
A. To create a scintigraphic system for measuring gastric emptying and to estimate the gastric
emptying parameters in Hp positive FD.
B. To investigate the role of Hp eradication therapy in gastric emptying after long-term follow-
up.
3. To assess the impact of specific properties of Hp gastritis in FD
      
A. To study whether topografic subtypes of Hp gastritis have different symptoms or treatment
response in FD.
B. To evaluate the role of the density of Hp in gastric mucosa and the role of the urease activity
in FD.
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4. MATERIALS AND METHODS
4.1 Study population
The original study population consisted of 151 HP positive patients with functional dyspepsia.
Patients were enrolled from the basic population of outpatients sent for gastroscopy by primary
care physicians or gastroenterologists during a 24-month period between October 1995 to
November 1997. The study was carried out at the Department of Gastroenterology in the
Helsinki University Central Hospital.  2150 patients were screened. In addition, 11 healthy
volunteers and 11 FD patients without Hp infection were included in the scintigraphic
examination as controls. A flowchart covering the patient flow during the12-month follow-up is
in Figure 1. The clinical characteristics of the study population are shown in Table 3. Prior to
the inclusion of the study patients, organic causes of dyspepsia were thoroughly ruled out by
normal physical examination, gastroscopy, upper abdominal ultrasound examination, lactose
absorption test, and appropriate haematological and biochemical tests. Patients with
predominant reflux symptoms or a history of previous gastrointestinal surgery were excluded.
None had evidence of any systemic disease or medication known to cause dyspepsia symptoms.
Prior to the study, every patient suffering from lactose intolerance remained for at least 3
months on a lactose-free diet. Before participation in the study, an informed consent was given
by every patient. 
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Table 3.
Clinical characteristics of the study population
Eradication therapy
and
 Omeprazole-treatment
Placebo
 and 
Omeprazole-treatment
N 77 74
Men 23 (30%) 29 (39%)
Mean age 51.5±9.5 51.8±11.8
Habitual smokers 40 (54%) 44 (59%)
NSAID use 1-3 tbl/week 17 (22%) 22 (30%)
NSAID use > 3tbl/week 11 (14%) 13 (17%)
Lactose intolerance 13 (17%) 13 (18%)
Irritable bowel syndrome 34 (44%) 36 (49%)
Chronic gastritis score 3.9±1.3 3.8±1.1
Dyspepsia score 10.4±3.3 10.2±2.9
4.2 Endoscopic and histological examination
The endoscopies were performed in the Helsinki University Central Hospital, at the Department
of Gastroenterology. In the study population, gastroscopy findings were either normal or
showed only minor inflammatory features (no ulcers, no erosions, no macroscopic oesophagitis
or duodenitis). At the endoscopy, two biopsies from lower duodenum, corpus and antrum were
taken as well as from any specific findings. In addition, Hp infection was confirmed by rapid
urease test and bacterial culture. Histology was considered the golden standard because the
patient was defined as Hp positive if either histology only, or two other tests without histology
were positive. Gastritis was graded according to the Sydney System (Price 1991). From the
randomized 151 patients, paired biopsy samples were insufficient in eight subjects, and
therefore different topographical elements of the gastritis were evaluated from 143 patients.
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Activity of gastritis was graded by the neutrophilic infiltration in gastric mucosa. Scores of the
activity of antrum gastritis (0-3) and corpus gastritis (0-3) were evaluated separately and the
sum score (0-6) stood for “total activity of gastritis”. As well, the severity of the chronic gastritis
was determined by the amount of mononuclear cell infiltration and inflammation was graded
separately for antrum (0-3) and for corpus (0-3). Thus, the “total chronic gastritis score” varied
between 0 and 6. Similar scores (antrum, corpus and total) were determined for atrophy and
intestinal metaplasia, and for the Hp load in gastric mucosa. Furthermore, the topografic type of
gastritis was named according to the mononuclear cell distribution. If the chronic gastritis score
for antrum was higher than the score for corpus, the subject was classified having an “antrum
predominant” gastritis. If the scores were equal, the patient was classified having a
“pangastritis”, and the rest of the cases were classified as  “corpus predominant”. After one year
follow-up, endoscopy and histological evaluation were repeated.
4.3 Questionnaires
The symptoms and the quality of life were evaluated by separate questionnaires. Dyspeptic
symptoms were evaluated by a unique numeric scale questionnaire after every 3 months during
the one-year follow-up. The questionnaire was a modified version from the questionnaire used
in a Finnish patient population by Heikkinen et al. (Heikkinen et al. 1995, Heikkinen et al.1998).
Symptoms evaluated were pain in the upper abdomen (score 1-4), bloating (1-2), heartburn (1-
6), early satiety (1-2), nausea (1-6), vomiting (1-6), night-time pain (1-2), regurgitation (1-6),
and hunger pain (1-2). A total dyspepsia score was determined based on ’ulcer-like’ symptoms
(pain, night-time pain, and hunger pain; 0-8) plus ’dysmotility-like’ symptoms (nausea and
bloating; 0-8). In study I, patients were divided into two subgroups (ulcer-like and dysmotility-
like) based on the most predominant symptom-scores. Diagnosis of irritable bowel syndrome
was made according to the criteria of Thompson et al. (1989). 
At baseline and 12 months later, quality of life was measured by a validated RAND 36-item
health survey 1.0 questionnaire, which is a cross-translated version of the SF-36 questionnaire
(Hays et al. 1993, Ware and Sherbourne 1992). It has been validated in a Finnish patient
population (Aalto et al. 1999). Quality of life was evaluated in eight different aspects. In
addition, change in general health was determined by one question.
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4.4 13C-urea breath test
13C-UBT was carried out in 36 patients according to the method described by Logan et al.
(1991). A single point breath sample was taken 30 min after ingestion of the 13C-urea. The
sampling procedure was identical to  that followed the collecting the baseline sample. All
samples were taken in duplicate. The 13C-enrichment in the expired breath was measured by
automated breath 13C- analysis, by means of continuous flow-isotope ratio mass spectrometry.
A DOB over 4‰ was considered positive, values between 2‰ and 4‰ were considered
inconclusive, and values below 2 ‰ were considered negative.
4.5 Scintigraphic measurement of gastric emptying
Gastric emptying was measured by a dynamic dual-tracer scintigraphic examination in 72
patients and again in 29 after one year. In addition, 11 healthy control subjects and 11 FD
patients without Hp infection were examined. After an overnight fast lasting at least 12 hr, the
subjects ate a warm 200g standard test meal within 5 min (lactose-free meat-cabbage casserole;
Ruoka-Saarioinen Oy, Sahalahti, Finland) labelled with 111-In (9.25 MBq). The energy content
of the meal was 220 kcal. After consuming the meal, the study subjects drank 150 ml 99mTc-
labelled (75 MBq) water just prior to the study. After the 5-min eating period, the patient was
placed in a supine imaging position. The dynamic double isotope examination with its 30-sec
acquisition time included images of the gastric area in anterior and posterior projections for a
total of 90 minutes. The regions of interest (ROIs) were drawn, including the areas of the entire
stomach, proximal (corpus) and distal (antrum) parts of the stomach and the distal part of the
oesophagus. The oesophageal ROI was drawn in order to detect any reflux that occurred during
the study. The background area was drawn outside, near the medial side of the stomach. The
time-activity curves were calculated as geometric means of the total counts of the anterior and
posterior ROIs. The mirrored ROIs were used for posterior-anterior images to produce
geometric mean values. The background subtraction was made by use of the information from
the background curve generated by the 111-In and 99m-Tc Compton scatter. The 50% post-lag
retention time (T50) for solid substance and the gastric emptying half-time (T1/2) for liquid
substance were determined separately from the dynamic curves. The lagtime in solid emptying
was determined at the turning point of the descending part of the time-activity curve of the
entire stomach. The intragastric distribution of solids was chosen to be calculated at 10 min as
a percentage ratio of the geometric means for the anterior and posterior ROI counts between the
antrum and the entire stomach. A scintigraphic image of a liquid emptying with the
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demonstration of ROIs is shown in Figure 2.
4.6 Medication
At baseline, patients received omeprazole 20mg daily for the first three months and thereafter
placebo during the follow up. In addition to the omeprazole treatment the patients were
randomised either for Hp eradication therapy or for placebo antibiotics. Of the 151 patients 77
received eradication therapy for the first 2 weeks with amoxycillin 500mg q.i.d, metronidazole
400mg t.i.d, and omeprazole 20mg b.i.d; 74 patients received omeprazole 20mg b.i.d and
placebo antibiotics. Randomisation was done in blocks of four and the randomisation list was
generated by the manufacturer of the treatment medicines by a computer-based method.
Investigators (pathologist, gastroenterologists, and other personnel) and patients were blinded
to all data until the study was fully completed. The only exception was the 3-month omeprazole
treatment, which was only single-blinded and was known to the investigators but not to the
patients. In addition, the patients were told not to use any other medication for dyspepsia, but
merely contact the study personnel if their symptoms worsened markedly. During the follow-up,
patients visited research assistants after each 3-month period for controlling the use of study-
medication and to return the symptom questionnaires.   
4.7 Statistical analysis
In study III, the patient population whose Hp eradication was successful was termed as a
successful eradication group, and patients whose Hp eradication failed or who received placebo
and remained Hp positive stood for controls. In studies I, II, III and V paired t-tests and
nonparametric tests (Mann-Whitney rank sum test and Kruskall-Wallis tests) were used for
comparing groups and linear regression analysis was used for analysing association between
continuous variables. In study IV, patients who received Hp eradication therapy and omeprazole
were named as treatment group, and patients who were treated with placebo-antibiotics and
omeprazole stood for controls. The changes in scores of various aspects of quality of life and the
changes in dyspepsia scores were compared between the treatment group and controls by means
of Mann-Whitney rank sum test. Patients with symptom score reduction of 50 % or more were
considered as responders, and Chi-square-test was used to evaluate the amount of responders
between treatment group and controls. Multiple regression analysis controlling for age, sex, 
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smoking habits, use of NSAIDs, Hp status, and irritable bowel syndrome was used in
multivariate analysis separately for total dyspepsia score and heartburn at the end of the 12-
month follow-up. Two-tailed p-values # 0.05 were considered statistically significant. Data was
analyzed by BMDB for windows system. All results are expressed as means ± SD.
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5. RESULTS
5.1 Gastric emptying
In study I, eleven healthy subjects were compared to twenty-five patients with functional
dyspepsia divided to either ulcus-like or dysmotility-like symptoms to create a standardized
double-tracer scintigraphic method. Gastric emptying half-time in patients with dysmotility-like
symptoms was 79.8±34.7 min for solids and 35.4±9.4 for liquids. Gastric emptying half-time in
patients with ulcer-like dyspepsia was 100.0±64.2 for solids and 35.2±8.8 for liquids. There was
no statistical difference in any of these parameters between patients and control subjects.
However, solid lag-time was prolonged in patients with dysmotility like dyspepsia compared to
controls (6.7±4.4 vs 2.5±3.1; p<0.05). Among patients with dysmotility-like symptoms
13.5±9.1% of the solid content was located in the antrum after 10 minutes of ingestion whereas
this proportion was 5.2±2.3% for controls (p<0.01). As well, the intragastric distribution for
liquids was more distal in patients with dysmotility-like symptoms (p<0.05). In study II, these
eleven healthy controls were compared to 83 patients with functional dyspepsia. In addition, the
anatomical settings (ROIs) for graphic evaluation of the data were reassessed and therefore the
“normal values” changed slightly. The values of gastric emptying parameters for healthy control
subjects are demonstrated in Table 4.
In study II, 94 subjects were examined and the gastric emptying parameters were compared
between patients with functional dyspepsia and healthy controls. In this larger patient population,
the prolonged solid lag time for dyspeptic patients (4.5±4.9 min vs 1.0±2.0; p<0.05), was the
only statistically significant difference in these parameters. However, the tendency for slower
gastric emptying and more distal gastric content distribution was seen among patients with
functional dyspepsia. The gastric emptying parameters for the 83 patients with functional
dyspepsia are seen in Table 4.
38
Table 4. Gastric emptying parameters for 83 patients with functional dyspepsia compared to
eleven healthy control subjects (normal values).
Parameter Value Normal values P
Gastric emptying for solids T50 
(min)
94.8 ± 57.6 77.4± 29.9  ns
Gastric emptying for liquids T1/2
(min)
34.6 ± 10.8 35.9 ± 11.2  ns
Intragastric distribution for solids 
(% in antrum after 10 minutes)
7.1 ± 5.8 6.1 ± 3.2  ns
Solid lag-time
(min)
4.5 ± 4.9 1.0 ± 2.0 Prolonged in
patients with
NSAID-use
(P<0.05)
The roles of various factors in gastric emptying parameters were tested in this population of 94
subjects. Parameters tested were sex, age, dyspeptic symptoms, Hp status, irritable bowel
symptoms, lactase deficiency, habitual smoking and use of NSAIDs. Hp gastritis and NSAID-use
were associated with prolonged solid lag-time (p<0.05) as well as dyspeptic symptoms (p<0.05).
However, after multivariate analysis the use of NSAIDs was the only statistically significant
factor. Delayed liquid emptying (T1/2) was associated with increasing age (p<0.025). Habitual
smoking was linked to more distally distributed gastric content in the stomach. Among males,
smokers had more rapid solid emptying (T50) (p<0.05).
The role of successful Hp eradication in gastric emptying after 12 months (study III) is
demonstrated in Table 5. 
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Table 5. Gastric emptying parameters between H.pylori-eradicated and placebo-treated
functional dyspepsia patients at the beginning of the study and one year after eradication therapy
(n=29).
Before H.pylori eradication           At one-year follow-up
Treatment
group
Placebo
group
p Treatment
group
Plecebo
group
p
T50/solids (min) 110.0+74.5 104.1+87.9 ns 104.3+61.0 86.1+44.3 ns
T1/2/liquids (min) 35.2+11.1 33.2+10.6 ns 33.2+9.6 33.7+9.9 ns
solid lagtime (min) 3.6+3.5 3.1+3.5 ns 4.1+3.1 4.9+2.9 ns
intragastric distribution
(% in antrum)
3.3+1.1 7.8+5.5 <0.05 5.6+3.2 * 8.4+4.0 ns
* p<0.05 compared with the baseline value
In this follow-up study, no differences were revealed between patients who had received a
successful Hp eradication therapy and patients with ongoing infection after one year. However,
this long-term prospective study showed the reproducibility of a scintigraphic gastric emptying
study. In the patient population, the association between the first examination and the one after
12 months follow-up was significant for both, solid gastric emptying (T50, p=0.20, R=0.43) and
liquid emptying (T1/2, p=0.018, R=0.43).
5.2 Treatment effect on dyspeptic symptoms and quality of life
The dyspepsia symptom scores at the beginning of the study, after cessation of omeprazole
treatment (3 months) and after the follow-up (12 months) are demonstrated  in Figure 3. 136
patients completed the one year follow-up. After 3-month omeprazole treatment, the total
dyspepsia symptom score diminished  from 10.4±3.3 to 7.6±2.9 in the treatment group and from
10.2±2.9 to 7.5±2.7 in the control group. No statistical difference was revealed in the changes of
dyspepsia scores between these groups. After the 12-month follow-up, the dyspepsia score was
7.4±3.0 in the treatment group with a mean symptom reduction of 28.8% compared to baseline.
In the control group the dyspepsia score was 7.6±3.1 with the mean symptom reduction of 21.7%
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(p=ns). In a multivariate model, female gender was the only factor independently related to
dyspeptic symptoms (p=0.02). The whole model accounted for 9% of dyspeptic symptoms. No
factor tested (Hp status, age, sex, use of NSAIDs, smoking habits, or irritable bowel) was related
to heartburn. In treatment group, 16 (20.8%) patients were considered as “responders” to the
treatment (symptom reduction at least 50%), whereas 11 (14.9%)  “responders” were found in
the control group (p=0.32). In analysis by Hp status after 12-month (per protocol analysis), the
symptom reduction was 30.4% in patients with successful Hp eradication and 22.2% among
those who remained Hp positive after 12-month follow-up (p=ns) (Table 6).
Table 6.
Outcomes of the symptom-evaluation at one year.
       Treatment                           Placebo
Change in
scores
95% CI Average
symptom
reduction
Change in
scores
95% CI Average
symptom
reduction
p
ITT
(by treatment
groups)
-3.1±3.4 -3.9- -2.2 28.8 % -2.2±3.0 - 3.0- -1.4 21.7 % 0.3
PP
(by Hp  status)
-3.2±3.5 -4.1– -2.4 30.4 % -2.1±3.0 -2.8– -1.4 22.2 % 0.1
In separate dyspeptic symptoms, a statistically significant reduction in nausea, vomiting,
bloating, heartburn, regurgitation, abdominal pain, and night-time pain was established in both
patient groups. Improvement in early satiety was seen only in the Hp eradicated patients. After
12 months’ follow-up, the statistically significant reduction in these seven symptoms was still
evident. However, heartburn (p<0.01) and regurgitation (p<0.001) revealed a relapse after
cessation of the 3-month omeprazole treatment in both patient groups (Figure 4). Statistically
significant relapse of  bloating (p<0.05) was seen in the Hp eradicated patients, and relapse of
nausea (p<0.05) occurred among the Hp positive, after this 3-month period with acid-
suppression therapy. 
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In analysis of quality of life, the changes in the nine aspects are illustrated in Figure 5. In the
treatment group, the bodily pain reduced (p<0.05), and in the control group the mental health
improved (p<0.05). General health improved in both patient groups (p<0.001), but this aspect
was evaluated only by one question. Although all the aspects of quality of life showed a clear
tendency to improve during the study, there was no difference between treatment group and
controls after the 12-month follow-up. 
5.3 Gastritis and dyspeptic symptoms
From the total of 143 patients 52% (74) had antrum-predominant gastritis, 38% (55) had
pangastritis and 10% (14) had corpus-predominant gastritis. The dyspepsia symptom scores in
separate types of chronic gastritis are shown in Table 7. There was no statistical difference in
any of the dyspepsia scores (total dyspepsia score, ulcuslike dyspepsia score, dysmotilitylike
dyspepsia score) between different types of gastritis prior to the medication. As well, the
severity of gastritis was not associated with the dyspeptic symptoms. Hp eradication rate was
100 % in patients with corpus-predominant gastritis compared to the 71% rate in antrum-
predominant gastritis and 88 % in pangastritis. However, there were only five patients in
eradication therapy group with corpus-predominant gastritis.

45
Table 7.
Properties of different gastritis subtypes at baseline.
Antrum-
predominant
Pangastritis Corpus-
predominant
Total
N 74  (52 %) 55  (38 %) 14  (10 %) 143
H.pylori
density score
3.7±1.3 3.8±1.3 2.5±1.2 3.6±1.4
Total gastritis
activity score
1.8±1.0 2.2±1.0 2.2±1.1 1.9±1.1
Total chronic
gastritis score
3.6±1.0 4.4±1.1 4.4±0.9 3.9±1.2
H.pylori
eradication
rate  ITT (%)
25/35 (71) 24/27  (88) 5/5 (100 ) 54/67 (81)
Total
dyspepsia
score
10.4±3.2 10.0±3.2 10.0±3.4 10.2±3.2
Ulcuslike
dyspepsia
score
5.1±1.5 4.9±1.5 4.8±1.3 5.0±1.4
Heartburn
score
4.0±2.0 4.1±2.1 3.7±1.8 4.0±2.0
Among subtypes of chronic gastritis, dyspepsia symptom score reduced significantly after the 3-
month omeprazole treatment in patients with successfully Hp eradicated corpus-predominant
gastritis compared to controls with corpus-predominant gastritis. However, the difference was
not seen after the whole 12-month follow-up. In patients with antrum-predominant gastritis, the
reduction of dyspepsia was more profound among successfully Hp eradicated, and the difference
increased significantly after the 12-month follow-up (Table 8., Figure 6.). In different subtypes
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of gastritis, no differences in ulcus-like dyspepsia or heartburn were seen between successfully
Hp eradicated patients and controls with ongoing infection during the follow-up. 
5.4. Urease activity 
Among the 36 patients whose urease activity was measured, the mean DOB-value was 43.3 ±
21.1. There was no association between the urease activity of the stomach and the total chronic
gastritis score (Figure 7.) or gastritis activity score. In addition, no association between Hp load
in gastric mucosa and the DOB-value of UBT was seen. However, the urease activity of the
stomach was associated with the subtype of chronic gastritis (Figure 7.). The mean DOB-value
in patients with antrum-predominant gastritis or pangastritis was 46.8 ± 20.5, whereas patients
with corpus-predominant gastritis had a mean DOB-value of 28.6 ± 20.0 (p<0.05). Furthermore,
the urease activity of the stomach was higher in patients with moderate or severe chronic
gastritis in antrum than in patients with mild or absent chronic antrumgastritis (Figure 7).
Patients with mild chronic gastritis in antrum (score 0-1) had a mean DOB-value of 14.2 ± 15.4,
and patients with moderate or severe antrumgastritis had a mean DOB-value of 45.9 ± 19.9
(p<0.05). 
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Table 8.
Change in dyspepsia scores in separate types of chronic gastritis among Hp eradicated patients
and patients who remained Hp positive after treatment.
  
                                                            After 3-month      After 12-month
  
                                                  omeprazole treatment      follow-up
H.pylori
eradicated
H.pylori
positive
p H.pylori
eradicated
H.pylori
positive
p
All patients -3.2 ± 2.9
 (-4.0- -2.5)
-2.3 ± 3.0 
(-3.0- -1.6)
0.07 -3.2 ± 3.5 
(-4.2- -2.4)
-2.1 ± 3.0 
(-2.9- -1.4)
0.13
Antrum-
predominant
gastritis
-3.7 ±2.7 
(-4.8- -2.5)
-2.8 ± 3.0 
(-3.9- -1.7)
0.12 -3.6 ± 2.9 
(-4.8- -2.3)
-1.7 ± 2.9 
(-2.7- -0.6)
0.05
Pangastritis -2.9 ± 3.3 
(-4.4- -1.5) 
-2.0 ± 3.2 
(-3.2- -0.7)
0.32 -2.8 ± 3.4 
(-4.3- -1.3)
-3.1 ± 3.2 
(-4.5- -1.8)
0.88
Corpus-
predominant
gastritis
-4.8 ± 3.0
 (-8.6- -1.0)
-0.9 ± 2.0 
(-2.6- 0.8)
0.03 -5.2 ± 6.4 
(-13.2-2.8)
0.0 ± 1.6 
(-1.3-1.3)
0.15
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6. DISCUSSION
6.1. Gastric emptying
We demonstrated a dual-tracer method to analyze the gastric emptying simultaneously for liquid
and solid contents. As is the problem with many other isotope-based gastric emptying tests,
many physiologic factors should be standardized to obtain a reliable result (Akkermans and Van
Isselt 1994). We used a standardazided test meal and a supine position, timing of the
imagination was equal (between 8 and 10 am) and the use of medication affecting gastric
emptying was not allowed prior to the examination. Gastric emptying parameters used (solid lag
time, solid postlag emptying rate and 50% emptying time for liquids) are generally accepted
(Akkermans and Van Isselt 1994). The shortcoming of our method was that cigarette smoking
was permitted before the imaging. Cigarette smoking has previously been shown to affect
gastric motility ((a)Scott et al. 1993, Hausken and Berstadt 1992). The number of control
subjects was limited and the range of normal values in the gastric emptying parameters remained
quite wide. This variability and the poor correlation between symptoms and altered gastric
emptying have previously been documented (Klauser et al 1993, Vantrappen 1994, Talley et al.
1989). Although, the follow-up study (III) was mainly planned to assess the effect of treatment
on gastric emptying, and not the reproducibility of our scintigraphic method, the data showed
gastric emptying rate to be stable after 12-months, whether Hp was eradicated or not. To our
knowledge, the long-term  reproducibility of isotope-based gastric emptying measurement has
not been previously documented. We consider our method to be a reliable tool for evaluating
gastric emptying also in selected clinical settings, for example diagnosing gastroparesis in
complicated cases or using this method in clinical research.
Theoretically, Hp may affect gastric emptying through several hypothetical mechanisms:
cytokines, inflammatory cell infiltration of the mucosa and changes in the secretion of some
gastrointestinal hormones (Go and Crowe 2000). However, studies on gastric emptying in
relationship to H.pylori infection have showed inconclusive results (Table 9)
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Table 9.
Studies on gastric emptying and H.pylori including present study.
Reference Patients Method Main results
Tucci et al. 45 FD  (27 Hp+, 18 Hp-) Scintigraphy, solid
meal
Delayed in FD
Delayed for Hp-
Miyaji et al. 46 FD (31 Hp+, 15 Hp-) scintigraphy, EGG,
eradication therapy, 2
month follow-up
Eradication therapy
normalized altered
(delayed or rapid)
gastric emptying
Chiloiro et al. 27 FD, 30 controls ultrasound, solid-
liquid meal
No differences between
groups, alterations in
gastric hormones in Hp+
Goh et al. 39 FD (20Hp+, 19Hp-), 
20 controls
Scintigraphy, solid
meal, eradication
therapy
No difference between
FD and controls or after
eradication therapy 
Rhee et al. 34 FD Scintigraphy, gastric
barostat
No differences in gastric
emptying or gastric
sensitivity between Hp+
and Hp-
Testoni et al. 38 FD (20 Hp+, 18 Hp-) Scintigraphy,
manometry
No difference in gastric
emptying gastritis+ or
gastritis-, reduction of
MMC of gastric phase
III in Hp+
Scott et al. 75 FD (25 Hp+, 50 Hp-) Dual-tracer
scintigraphy, solid
and liquid meal
Longer solid lagtime for
Hp-, altered intragastric
distribution in FD
Caballero-
Plasencia et al.
50 FD, 10 controls Scintigraphy, solid
meal
Delayed in FD, no
difference in Hp+ and
Hp-
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Reference Patients Method Main results
Parente et al. 38 FD, Hp+ Eradication therapy or
ranitidine, 6 month
follow-up, solid meal
No difference in gastric
emptying or acid
secretion, reduced
gastrin and PGI after
eradication 
Perri et al. 304 FD (208 Hp+) 13C-octanoic acid
breath test, solid meal
No difference between
Hp+ and Hp-, delayed
emptying associated
with postprandial
fullness and nausea
Chang et al. 60 FD (38 Hp+, 22 Hp-) Scintigraphy, solid
meal
Delayed in FD, no
difference in Hp+ and
Hp-
Saslow et al. 16 controls (8 Hp+, 8 Hp-) Scintigraphy, solid
meal
No difference in Hp+
and Hp-
Fock et al. 72 FD, (23 Hp+, 49 Hp-),
32 controls
Gastric emptying of
radio-opaque markers
Delayed in FD, delayed
in Hp+
Present study
(II)
83 FD (72 Hp+, 11 Hp-), 
11 controls
Dual-tracer
scintigraphy, solid
and liquid meal
Prolonged solid lagtime
in NSAID users,
alterations in smokers,
delayed liquid emptying
in older subjects
Present study
(III)
29 Hp+ FD and 11 controls Dual-tracer
scintigraphy, solid
and liquid meal, 12
month follow-up after
Hpylori eradication
No difference between
Hp+ and Hp eradicated
after 12-months, stable
individual gastric
emptying rate
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We found a trend of delayed gastric emptying among FD patients but the finding was not
statistically significant. In overall, delayed gastric emptying in FD patients seems to vary
between 30% to 80% in published studies (Klauser et al. 1993, Malagelada 1991, Quartero et al.
1998), and the significance of this weak association between FD and prolonged gastric emptying
may have only minor clinical impact. We demonstrated prolonged solid lag time especially in
Hp positive subjects. Scott et al. ((b)1993) have reported an opposite finding but they have
excluded patients with ulcerlike dyspepsia. This is an interesting finding because antral part of
the stomach with peristaltic contractions is associated with gastric emptying rate of solids
(Minami and McCallum 1984). In our study considering the treatment response of FD by
eradicating Hp, patients with antrum-predominant gastritis got benefit from the eradication
therapy. In addition, antral hypomotility has been demonstrated among Hp positive FD patients
(Mearin et al. 1995), and improvement of gastric hypomotility has been documented after
successful Hp eradication (Thor et al. 1996). Conversely, Pieramico et al. (1993), did not find
differences in postprandial antral motility between Hp positive and negative patients. Studies on
gastric motility between different subtypes of Hp gastritis have not been performed. Severe
antrum-predominant chronic gastritis may have a role in altered gastric emptying, especially of
solid contents.
6.2. Symptoms and quality of life after H.pylori eradication
Although in general, the aspects of quality of life showed a clear tendency for improvement in
both treatment groups (Figure 5.), the reduction in bodily pain (p<0.05) in treatment group and
the improvement of mental health (p<0.05) were the only statistically significant changes. After
12-months, no clear difference in quality of life was demonstrated between groups. The quality
of life outcome in our study was very similar to the one in the study by Blum et al. (1998).
Therefore, we can conclude that this measurement tool can not demonstrate any treatment effect
favouring H.pylori eradication in functional dyspepsia. However, the role of placebo effect was
clearly observed.
Adequately performed H.pylori eradication studies in functional dyspepsia, including the
present study, are demonstrated in Table 10.
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Table 10.
Studies of H.pylori eradication treatment in functional dyspepsia
Study N Symptom
assessing 
Medication Control of
extra acid-
suppression
Follow-
up time
Study
design
Other Result / Conclusion
Present
study
151 Numeric scale
questionnaire and
RAND-36 (quality
of life)
Eradication
therapy vs
placebo
antibiotics and
3kk omeprazole
for all patients
3 kk omeprazole
treatment for all
patients, no extra
medication
12 months Single-
center
No  differences in changes of
symptom or quality of life
scores
Talley -
99
(BMJ)
278 Gastrointestinal
symptom rating
scale and the
Psychological
general well being
index
ome+amo+cla (1
week) vs placebo
A weak antacid was
dispensed to patients
and extra medication
was monitored
12 months Multi-
center (40
centres)
Moderate or
severe gastritis
was associated
to impaired
treatment
success
No difference in treatment
success between groups
Greenbe
rg -99
(ArchInt
ernMed)
100 visual analog
symptom scale
ome+cla (2
weeks) vs
placebo
no extra medication 12 months Single-
center
HP eradication
only 71%
No difference in change of 
symptom score 
Talley -
99
(NenglJ
Med)
293 Gastrointestinal
Symptom Rating
Scale and diary
cards and SF-36
(quality of life)
ome+amo+cla (2
weeks) vs
placebo
A weak antacid was
dispensed to patients
12 months Multicenter No differences between groups
in symptoms or quality of life
Blum-
98
(NEnglJ
Med)
348 Likert scale diary
cards and
Gastrointestinal
symptom rating
scale and
psychological ell
being index
ome+amo+cla
(one week) vs
ome+placebo
Not known 12 months Multicenter Hp eradication
rate only 79%
No differences between groups
in symptoms or quality of life 
McColl
-98
(NEnglJ
Med
330 Glasgow
dyspepsia severity
score and SF-36
(quality of life)
ome+amo/tetra+
metro (2 weeks)
vs placebo+ome
Use of extra
medication included
in the score system
12 months Single-
center
No endoscopy at
the end of the
follow-up
Resolution of symptoms
associated with eradication
therapy, no differences in
dyspepsia scores, long history
of dyspepsia associated to poor
treatment success
Froechli
ch -01
(Am J
Gastroe
nterol)
144 SF-12
Questionnaire
lan+amo+kla (1
week) vs
lan+placebo
Use of extra
medication was
monitored
12 months Multicenter No difference between groups
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The common problem in these studies is the different outcome measure of dyspeptic symptoms.
Other problem is the extra medication used, which is in general poorly controlled. Acid-
suppressing therapy, especially with PPIs, is nowadays the most used treatment in FD (Ryder et
al. 1994), and recent studies have shown a positive effect on symptoms of FD by PPI treatment
(Meinache-Schmidt et al. 1999, Talley et al. 1998). In our study, the acid suppression was
standardized by using an initial 3-month omeprazole treatment for all patients. However,
shortcoming of our study is the questionnaire. Although, it has previously been used in Finnish
patient population (Heikkinen et al.1995 and 1998), it has not been planned for scoring
dyspeptic symptoms. In contrast, our SF-36-questionnaire measuring quality of life, has been
cross-translated and validated. In general, direct translations from different questionnaires can
not be used. For example, the terms “heartburn”, “halsbränna” and “närästys” may have very
different meanings among dyspeptic patients. In addition, the Glascow dyspepsia severity score
(McColl et al. 1998) including home visits by doctors can not be used in Finnish health-care
system. 
As is the case in most studies published, the patient selection is based on past medical history
and gastroscopy findings. It is impossible by these means to totally rule out patients with reflux
disease, although the symptom analysis has been considered as the most useful method for
diagnosing reflux disease (Dent 1998). In the present study, improvement in pain, heartburn,
regurgitation, and nausea after the omeprazole treatment  of three months was clear, although
patients with predominant reflux symptoms had been excluded. This positive effect was
maintained during the rest of the follow-up and it was obvious whether the Hp was eradicated
or not. Treatment with PPIs has shown positive effect in patients with ulcerlike or refluxlike
dyspeptic symptoms (Farup et al. 1999, Talley et al. 1998). However, no treatment studies in Hp
positive FD with previous oesophageal pH monitoring exist. Also in our data, the reflux-like
symptoms showed a clear relapse after cessation of omeprazole therapy in both patient groups,
and it points to the conclusion that the effect of omeprazole treatment disappeared and patients
with NERD may have been included. However, we demonstrated a sustained resolution of other
dyspeptic symptoms. In our opinion, we can not be sure whether this long-term symptom
improvement was due to omeprazole treatment or to placebo effect. Also in follow-up studies
without prolonged acid-suppressing therapy ((b)(c)(Talley et al. 1999, McColl et al.1998, Blum
et al. 1998), a clear improvement of dyspeptic symptoms has been achieved in treatment group
and controls. This points to the conclusion that the placebo-effect on treatment of Hp-positive
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FD is marked (vanZanten et al. 1996, Grant Thompson 2000). Two recent meta-analyses
handling treatment of Hp positive FD have reached opposite conclusions (Laine et al. 2000,
(b)Moayyedi et al. 2000). Four of five treatment studies, including present study, have shown no
effect on treatment of Hp in symptoms of FD (Table 10). However, all studies have shown a
mild tendency favouring Hp eradication. More detailed studies with careful patient inclusions
(oesophageal pH-monitoring, controlling extra-medications, evaluating different subtypes of
gastritis) are needed to verify the real association between Hp infection and FD. So far in
clinical practice, the benefit from eradicating Hp from patients with FD seems to have a minor
impact on symptom reduction.
6.3. Subtypes of gastritis and urease activity of the stomach
Chronic active gastritis affecting the antrum is associated with duodenal ulcer disease, whereas
fundus-predominant gastritis mainly leads to loss of acid secretory capacity and atrophy
(Sipponen et al.1989, 1990, 1993, McColl et al. 2000). As discussed earlier, the role of Hp
gastritis on dyspeptic symptoms, without ulcer-disease, is still unclear. However, the role of
different topographic types of gastritis on functional dyspepsia has been documented
insufficiently. There is evidence that antral gastritis is associated with ulcus-like symptoms in
FD (Trespi et al. 1994). In addition, improvement of dyspeptic symptoms has been associated to
healing of chronic gastritis in the study by Talley et al.(c)(1999). On the other hand, no
difference has been shown between FD and DU patients in the severity of corpus gastritis in Hp-
positive subjects (Khulusi et al. 1995). In the present study, no difference in symptom reduction
between successfully Hp eradicated patients and controls was seen, but the subgroup with
antrum-predominant chronic gastritis showed a clear benefit from this therapy. Chronic antrum-
predominant gastritis subsides slowly, and there is evidence that12 months after eradication
almost half of the patients  still have persistent chronic antrumgastritis (Valle et al. 1991).
Probably, a more profound effect on the symptoms in patients with antrum-predominant Hp
positive gastritis would have been seen, if we had had a longer follow-up period. Interestingly,
prolonged acid-suppression therapy improves Hp induced gastritis in antrum but aggravates
gastritis parameters in corpus, and it may even suppress Hp load in gastric mucosa (Stolte et al.
1998, Meining et al. 1998). This may partly clarify our positive treatment result in this antrum-
predominant gastritis subtype. Is the antrum-predominant Hp positive active gastritis only a
subtype of chronic peptic ulcer disease? The finding in our study concerning the best long-term
treatment response after successful Hp eradication in patients with antrum-predominant gastritis
57
has similarities to peptic ulcer disease. Previously, antrumgastritis has been strongly linked to
peptic ulcer disease, and as discussed earlier, ulcer-like symptoms have been linked to Hp
positive functional dyspepsia.
It is known that urease is a virulence factor and it is essential for Hp colonisation (Tsuda et al.
1994). There is also evidence that ammonia generated by the action of urease causes histological
damage in epithelial cells, and therefore it plays an important role in the inflammation process
(Eaton et al. 1991). In addition, DU patients have shown to have higher gastric biopsy urease
activity than FD patients with Hp infection (Khulusi et al. 1995). In clinical practice, 13C-UBT
is used to detect the Hp status non-invasively. In our study, it was used to detect the quantity of
total urease activity in the stomach at the moment the biopsies were taken. We noticed that the
urease activity of patients with antrum-predominant gastritis or pangastritis is higher than in
patients with corpus-predominant gastritis. Furthermore, the urease activity increased with the
increasing severity of chronic antrumgastritis. This may have some implications in clinical
practice to evaluate patients who will get benefit for their symptoms with Hp eradication.
6.4. Clinical applications and suggestion for management of functional dyspepsia
Dyspeptic patients are very common in clinical practice and it is not possible or reasonable to
profoundly investigate each dyspeptic patient. Missing gastric or esophageal malignancy is the
shortcoming of the strategy to investigate dyspeptic patients noninvasively only. If population
over 40 years with dyspeptic symptoms is endoscopied, 70% of gastric cancers were diagnosed
by investigating just 1% of population (Mollmann 1981 ). In other studies (O'Hanlon et al.
1996, Hallisey et al. 1990, Christie et al. 1997), the age-recommendation for endoscopying
dyspeptic patients varies between 40 to 55 years. By previous patient history, an evaluation of
other possible diseases causing dyspeptic symptoms should be done. These conditions are for
example inferior  ischaemic heart disease causing dyspepsia-like symptoms, biliary-tract
problems, connective tissue diseases causing GI-motility problems and few endocrinologic
diseases. Use of NSAIDs should be asked but most important is the evaluation of classical
“alarm symptoms”. These include problems in swallowing, weight-loss, fever or suspicion of
bleeding from GI-tract (anaemia, haematemesis, melena). Patients having these symptoms
should be carefully investigated. Patients having reflux-like symptoms, heartburn and
regurgitation, very  likely have reflux-disease, because a typical anamnesis is known to be
specific for this condition (Klauser et al. 1990). Therefore, patients with predominantly reflux-
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like symptoms should be treated according to reflux-disease. 
Hp eradication therapy  is reasonable based on the knowledge that at least patients with ulcer-
disease, and according to present study, patients with antrum-predominant gastritis get benefit
for their symptoms after successful Hp eradication. In “functional dyspepsia”, antrum-
predominant Hp gastritis may even represent a subtype of chronic peptic ulcer disease, because
if a subject with Hp gastritis is endoscopied only once, the signs of ulcer may not be present at
the moment. In addition, the long-term risks of Hp gastritis are marked (chapter 2.2.2) and
colonisation of gastric mucosa by Hp can not be considered as normal flora. Therefore, it is
questionable to classify Hp positive subjects in “functional dyspepsia”. In clinical practice, it is
logical to give eradication therapy to Hp positive patients with upper abdominal symptoms and
no contraindications for the medication. As a non-invasive test to detect Hp, 13C-UBT,
quantitative serology or antigen detection from a stool sample are recommended (Niemelä et al.
2000). As it was shown in present study, the quantitative result of 13C-UBT may detect patients
with favourable eradication treatment effect in Hp positive gastritis without ulcer-disease.
Optimal symptomatic treatment of FD patients is not easy. Treatment responses with PPIs, H2-
blockers or prokinetics are best documented, although the treatment effect may be marginal (Soo
et al. 2001, van Zanten et al. 1996).  As it is shown in the present study, the placebo-effect of
treatment is marked, but at least, patients with reflux-like symptoms will get benefit from PPI
therapy.  Cisapride has been associated with serious arythmogenic side-effects (Napolitano et al.
2000, McMullin et al. 1999) and therefore using it in the treatment of “benign” dyspeptic
symptoms is not justifiable. As it is shown in this study, the delayed gastric emptying may have
only minor impact on symptoms of functional dyspepsia. However, cisapride still has an
important role in the treatment of GI-tract motility disorders including diabetic gastroparesis.
Scintigraphic gastric emptying study can be helpful in patients with problematic symptoms
suggesting gastroparesis but no evidence of gastric retention in endoscopy. Colon irritable-
symptoms are often linked with functional dyspepsia, and treatment with fibre-products or with
anticholinergic agents may be useful in some cases. In the future, agents targeted to 5-HT-
receptors will probably be helpful in the treatment of irritable bowel syndrome. There are only
limited data considering the treatment of dyspepsia with psychiatric medication. In functional
chest-pain, treatment with anti-depressive agents has been useful and it could be worth trying in
some patients with functional dyspepsia (Fisher and Parkman 1998).
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In conclusion, the most important part in treating dyspepsia, is to rule out a possible organic
disease. Thereafter the treatment is planned based on patients’ Hp status, age and symptom
pattern. Each patient should be treated individually but general treatment strategies are useful
tools in practice. Based on these facts, an algorithm (modified from The European Helicobacter
pylori study group 1997) for investigating dyspeptic patients is expressed in Figure 8.
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7. CONCLUSIONS
1. In general, Hp positive patients with functional dyspepsia did not get benefit for their
symptoms by eradication therapy, but at least refluxlike symptoms were improved with
omeprazole treatment. Placebo effect on treatment was marked.
2. Dual-tracer scintigraphic examination of gastric emptying was reproducible and revealed that
the individual gastric emptying rate in patients with FD was stable during one year. Although
FD symptoms and Hp infection were associated with prolonged solid lagtime, no major
alterations in gastric emptying were seen between FD patients and controls. Hp eradication had
no effect on gastric emptying parameters during 12 months.
3. Hp positive antrum-predominant gastritis in patients with FD was associated with positive
treatment effect by eradicating Hp. High urease activity detected by 13C-UBT of the stomach
was associated with antrum-predominant gastritis or pangastritis in these patients. Hp density in
gastric mucosa did not correlate with the severity of symptoms of FD.
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